Compare Church & Dwight Co., Inc. (CHD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Church & Dwight Co., Inc. trades at $102.84 (market cap $24.38B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Church & Dwight Co., Inc. pays a 1.2% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| CHD | XBI | |
|---|---|---|
Market Cap | $24.38B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $105.26 | $164.28 |
52-Week Low | $81.60 | $86.92 |
Enterprise Value | $26.38B | — |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Church & Dwight (CHD) trades at $101.56, down 1.68% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results with 5.8% organic sales growth, beating expectations, and raised full-year guidance. Valuation ratios are elevated with a P/E of 32.94, while profitability remains solid with a net income margin of 11.96%.
Outlook is positive driven by volume growth and market share gains, but risks include high valuation and competitive pressures. Analysts are bullish with a $103.57 consensus target, offering modest upside from current levels amid steady cash flows and dividend payments.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
